News from sysmex inostics gmbh A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Sep 08, 2020, 06:00 ET Sysmex Inostics' Liquid Biopsy Testing Benefits Metastatic Pancreatic Cancer Patient Management

Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating cell-free tumor DNA (ctDNA) analysis for oncology, today announces the...


Aug 27, 2020, 06:00 ET Sysmex Inostics' OncoBEAMTM RAS CRC testing supports clinical outcome improvements for metastatic colorectal cancer patients rechallenged with anti-EGFR therapy

Sysmex Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the...


Aug 05, 2020, 06:00 ET Sysmex-Inostics Colorectal Cancer Blood-Based OncoBEAMTM RAS CE-IVD Test Shows Concordance with Standard of Care Tissue-Based RAS Testing

Sysmex-Inostics, Inc., a global leader and pioneer in blood-based circulating tumor DNA (ctDNA) analysis for oncology, today announces the...


Mar 10, 2020, 07:00 ET Sysmex Inostics' Updated SafeSEQ Breast Cancer Panel Advances Novel Clinical Uses of ctDNA Through Quantitative Testing

Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer...


Mar 09, 2020, 13:27 ET Sysmex Inostics' Updated SafeSEQ Breast Cancer Panel Advances Novel Clinical Uses of ctDNA Through Quantitative Testing

Building on the ultra-high sensitivity SafeSEQ Breast Cancer Panel circulating tumor DNA (ctDNA) test launched at the American Association of Cancer...


Jan 28, 2020, 06:00 ET Sysmex Inostics and Oxford Gene Technology Plasma and Tissue Sequencing Show Clearance of ctDNA Correlates With Pathologic Complete Response in Breast Cancer Patients During Neoadjuvant Treatment

Pathologist Dr. Vincente Peg of the Vall d´Hebron University Hospital (Barcelona Spain) and colleagues have presented a correlation between the...


Dec 16, 2019, 06:00 ET Sysmex Inostics Announces First Results of Tissue-independent Liquid Biopsy for Early Stage Breast Cancer Mutation Characterization and Monitoring Using Ultra-sensitive SafeSEQ Technology

New data presented by Dr. Ben Ho Park, Professor of Medicine and Director of Precision Oncology at Vanderbilt University and colleagues at the recent ...


Sep 27, 2019, 06:00 ET Sysmex Inostics Launches Two NGS-based Liquid Biopsy Panels for Cancer Therapy Drug Development

Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom...


Sep 04, 2019, 06:00 ET Sysmex Inostics Publishes First Feasibility Study of NGS-based Liquid Biopsy to Complement Early Breast Cancer Screening by Imaging

Using Sysmex Inostics' novel SafeSEQ next-generation sequencing cell-free DNA technology, investigators from the Biomedical Research Institute of...


Aug 02, 2019, 02:00 ET Sysmex Obtains Japanese Manufacturing and Marketing Approval for the First Blood-based RAS Mutation Testing for Colorectal Cancer

Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM™ RAS CRC Kit, used for blood-based circulating tumor...


Jul 18, 2019, 06:00 ET Liquid Biopsy Performance Comparison of Sysmex Inostics OncoBEAM RAS CRC and BioCartis Idylla ctKRAS Testing Published in Scientific Reports (Nature Journal)

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces...


May 30, 2019, 06:00 ET Sysmex Inostics OncoBEAM™-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study

Sysmex Inostics announces the publication of clinical research conducted as part of the CIRculating CANcer (CIRCAN) Program at the Lyon Cancer...


May 28, 2019, 06:50 ET Sysmex Inostics' SafeSEQ ER+/HER2- Breast Cancer Panel Demonstrates Equivalent Sensitivity to OncoBEAM™ Enhanced Digital PCR Technology for Detection of Mutations in Circulating Tumor DNA

Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast...


Feb 25, 2019, 06:00 ET Sysmex Inostics' OncoBEAM™ Demonstrates Clinical Validity and Superior Performance Versus Pan-cancer NGS for Blood-based Mutation Detection for Hepatocellular Carcinoma

Data recently published in Clinical Cancer Research demonstrate the advantages of using an ultra-high sensitivity test for detection of mutations...


Nov 05, 2018, 06:00 ET Sysmex Inostics OncoBEAM™ Circulating Tumor DNA Technology Demonstrates Superior Response Prediction for Advanced Pancreatic Cancer over Standard-of-care Protein Biomarkers

Recent data published in Annals of Oncology from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA...


Oct 18, 2018, 06:00 ET Sysmex Inostics' OncoBEAM™ Platform Demonstrates Superior Detection of Clinically-relevant Mutations for Therapy Selection and Molecular Monitoring for Lung and Colon Cancers

Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups...


Oct 15, 2018, 06:37 ET Sysmex Inostics' OncoBEAM™ Liquid Biopsy Technology Demonstrates Utility for Clinical Management of Melanoma Patients Undergoing Treatment With Targeted Therapy and Immune Checkpoint Inhibitors

Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce...


Sep 28, 2018, 06:00 ET Sysmex Inostics Announces Launch of OncoBEAMTM EGFR Kit v2 (RUO) in Europe and Asia

Sysmex Inostics, a subsidiary of Sysmex Corporation and a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular...


May 31, 2018, 06:00 ET Clinical Evaluation of Sysmex Inostics' Plasma NGS Liquid Biopsy Technology to Complement Mammography When Screening for Early Stage Breast Cancer Presented at the 2018 ASCO Annual Meeting

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis, today announced that preliminary clinical results of a novel...


Apr 13, 2018, 06:00 ET Sysmex Inostics Expands OncoBEAM™ Liquid Biopsy Testing in the U.S. to Assist Clinicians and Patients

Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics...


Jan 22, 2018, 06:00 ET In Depth: Performance Comparison of OncoBEAM™ RAS CRC and Idylla™ ctKRAS Liquid Biopsy Testing for KRAS Mutation Detection Presented at ASCO GI 2018

Sysmex Inostics, a global leader in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today highlights...


Jan 17, 2018, 07:00 ET Liquid Biopsy Performance Comparison of OncoBEAM RAS CRC and Idylla ctKRAS Testing Presented at ASCO GI 2018 Meeting

Sysmex Inostics, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, today announces data...


Nov 21, 2017, 05:00 ET Expert Taskforce Recommendation of OncoBEAM™ RAS CRC Liquid Biopsy Testing in Routine Clinical Practice for Colorectal Cancer Patients

Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics...


Sep 26, 2017, 06:00 ET OncoBEAM[TM] EGFR Kit (RUO) at Jessenius Medical Faculty of Comenius University and its University Hospital, in Martin, Slovakia

The launch is the first of its kind and will widen the use of of BEAMing technology in lung cancer area. Sysmex Inostics, a subsidiary of Sysmex...


Jul 05, 2016, 02:00 ET Sysmex Inostics Blood-based RAS Biomarker Test Now Available in Italy

Assessing RAS mutation status in patients with mCRC has shown that anti-epidermal growth factor receptor (EGFR) monoclonal antibody therapies can...